

Yann Neuzillet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9262022/publications.pdf>

Version: 2024-02-01

106
papers

6,999
citations

87723

38
h-index

66788

78
g-index

178
all docs

178
docs citations

178
times ranked

6893
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	0.9	1,241
2	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	0.9	1,152
3	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	5.8	304
4	Accuracy and Clinical Role of Fine Needle Percutaneous Biopsy With Computerized Tomography Guidance of Small (Less Than 4.0 Cm) Renal Masses. <i>Journal of Urology</i> , 2004, 171, 1802-1805.	0.2	288
5	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	5.1	229
6	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. <i>Cell Reports</i> , 2014, 9, 1235-1245.	2.9	181
7	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	0.9	158
8	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
9	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 589-594.	1.4	125
10	Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. <i>BJU International</i> , 2012, 110, 1134-1141.	1.3	105
11	EAU – ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
12	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324.	2.1	90
13	De novo renal cell carcinoma of native kidney in renal transplant recipients. <i>Cancer</i> , 2005, 103, 251-257.	2.0	86
14	Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. <i>British Journal of Cancer</i> , 2012, 106, 1083-1088.	2.9	84
15	Assessment of Oncologic Control Obtained After Open Versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinomas (UUT-UCs): Results from a Large French Multicenter Collaborative Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 301-308.	0.7	84
16	Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population. <i>European Urology</i> , 2011, 60, 366-373.	0.9	82
17	De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study. <i>American Journal of Transplantation</i> , 2012, 12, 3308-3315.	2.6	82
18	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81

#	ARTICLE	IF	CITATIONS
19	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
20	Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. <i>Urology</i> , 2005, 66, 1181-1185.	0.5	74
21	Influence of Positive Surgical Margin Status After Radical Nephroureterectomy on Upper Urinary Tract Urothelial Carcinoma Survival. <i>Annals of Surgical Oncology</i> , 2012, 19, 3613-3620.	0.7	72
22	Prostate cancer in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2374-2380.	0.4	64
23	Systematic review of the oncological and functional outcomes of pelvic organâ€preserving radical cystectomy (<scp>RC</scp>) compared with standard <scp>RC</scp> in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. <i>BJU International</i> , 2017, 120, 12-24.	1.3	63
24	Postoperative nomogram to predict cancerâ€specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. <i>BJU International</i> , 2014, 114, 733-740.	1.3	62
25	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	2.6	61
26	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. <i>European Urology</i> , 2020, 78, 682-687.	0.9	57
27	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.	0.6	49
28	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. <i>European Radiology</i> , 2019, 29, 4286-4293.	2.3	48
29	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. <i>PLoS ONE</i> , 2012, 7, e48993.	1.1	47
30	Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?. <i>BJU International</i> , 2012, 110, E570-3.	1.3	44
31	Recurrent activating mutations of PPARÎ³ associated with luminal bladder tumors. <i>Nature Communications</i> , 2019, 10, 253.	5.8	44
32	Morbidity of Retropubic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Multicenter Study from Renal Transplantation Committee of French Urological Association. <i>Urology</i> , 2008, 72, 1366-1370.	0.5	42
33	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. <i>European Journal of Cancer</i> , 2013, 49, 431-438.	1.3	41
34	High Incidence of Predominant Gleason Pattern 4 Localized Prostate Cancer is Associated With Low Serum Testosterone. <i>Journal of Urology</i> , 2011, 186, 1400-1405.	0.2	40
35	Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in nonâ€metastatic carcinoma invading bladder muscle: results from a nationwide caseâ€control study. <i>BJU International</i> , 2013, 111, 1253-1260.	1.3	36
36	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 549-560.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Long-Term Women-Reported Quality of Life After Radical Cystectomy and Orthotopic Ileal Neobladder Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 1398-1404.	0.7	32
38	French results of the ARESC Study: Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 66-75.	5.1	31
39	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	0.9	31
40	A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. <i>Andrology</i> , 2013, 1, 223-228.	1.9	30
41	The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. <i>BJU International</i> , 2012, 110, E1035-40.	1.3	28
42	European Association of Urology Guidelines on Primary Urethral Carcinoma—2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	2.6	28
43	Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1724-1730.	0.5	27
44	Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 382-387.	2.0	26
45	Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1135-1140.	0.8	25
46	Effectiveness of a cranberry (<i>Vaccinium macrocarpon</i>) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 165-168.	1.4	23
47	Landmarks in non-muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 476-480.	1.9	23
48	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 207-213.	1.4	23
49	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. <i>Hormones and Cancer</i> , 2019, 10, 36-44.	4.9	23
50	Clinicopathological Characteristics of Incidental Prostate Cancer Discovered from Radical Cystoprostatectomy Specimen: A Multicenter French Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 684-690.	0.7	22
51	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	1.2	22
52	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
53	Patterns of local recurrence after radical cystectomy in a contemporary series of patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2012, 30, 821-826.	1.2	21
54	Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. <i>BJU International</i> , 2012, 110, 1736-1741.	1.3	21

#	ARTICLE	IF	CITATIONS
55	The Z-shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients. <i>BJU International</i> , 2011, 108, 596-602.	1.3	20
56	Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. <i>World Journal of Urology</i> , 2013, 31, 83-91.	1.2	20
57	Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study. <i>BJU International</i> , 2015, 115, 87-93.	1.3	19
58	Trends in Renal Function After Radical Cystectomy and Ileal Conduit Diversion: New Insights Regarding Estimated Glomerular Filtration Rate Variations. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e139-e144.	0.9	18
59	Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue. <i>Journal of Developmental and Physical Disabilities</i> , 2012, 35, 860-866.	3.6	17
60	Positive surgical margins after radical prostatectomy: What should we care about?. <i>World Journal of Urology</i> , 2015, 33, 1973-1978.	1.2	17
61	Management of renal transplant urolithiasis: a multicentre study by the French Urology Association Transplantation Committee. <i>World Journal of Urology</i> , 2018, 36, 105-109.	1.2	17
62	Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. <i>PLoS ONE</i> , 2019, 14, e0211721.	1.1	17
63	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	1.3	16
64	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
65	Cleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score. <i>Urologia Internationalis</i> , 2017, 99, 156-161.	0.6	15
66	Effects of the Molecular Weight of Peg Molecules (8, 20 and 35 KDA) on Cell Function and Allograft Survival Prolongation in Pancreatic Islets Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 2354-2355.	0.3	14
67	Long-term follow-up of TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e1-20.e7.	0.8	13
68	Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial). <i>Prostate</i> , 2017, 77, 1512-1519.	1.2	13
69	Characteristics of undetected prostate cancer on diffusion-weighted MR Imaging at 3-Tesla with a b-value of 2000s/mm ² : Imaging-pathologic correlation. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 923-929.	1.8	12
70	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	0.9	12
71	Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 1811-1823.	1.1	12
72	Idiopathic Infantile Bladder Lithiasis from Roman Antiquity. <i>Urology</i> , 2011, 78, 1-2.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3833-3838.	0.7	11
74	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , 2020, 39, 4055-4065.	1.2	11
75	Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial). <i>Prostate</i> , 2019, 79, 272-280.	1.2	9
76	Online Public Interest in Urological Cancers During the COVID-19 Pandemic: What Can "Dr. Google" Teach Us?. <i>European Urology Open Science</i> , 2022, 37, 73-79.	0.2	9
77	Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patients. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 2, 191-201.	0.3	8
78	Indication and timing of cystectomy in high-risk bladder cancer. <i>Current Opinion in Urology</i> , 2012, 22, 427-431.	0.9	7
79	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology "Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	1.6	7
80	Concentration and Chain Length of Polyethylene Glycol in Islet Isolation Solution: Evaluation in a Pancreatic Islet Transplantation Model. <i>Cell Transplantation</i> , 2012, 21, 2079-2088.	1.2	6
81	ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4589-TPS4589.	0.8	6
82	Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. <i>International Journal of Urology</i> , 2009, 16, 855-861.	0.5	5
83	Obesity and hypogonadism are associated with an increased risk of predominant Gleason 4 pattern on radical prostatectomy specimen. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 22, 101-9.	0.3	5
84	Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16145.	1.6	5
85	PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. <i>World Journal of Urology</i> , 2021, 39, 2945-2951.	1.2	5
86	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvic/ureteral System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. <i>European Urology Focus</i> , 2021, 7, 1075-1083.	1.6	5
87	Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study. <i>Prostate</i> , 2019, 79, 1640-1646.	1.2	4
88	A review of new hormonal therapies for prostate cancer in black men: is there enough data?. <i>BMC Cancer</i> , 2021, 21, 61.	1.1	4
89	PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non-muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4550-4550.	0.8	3
90	Management of long ureteral stenosis: Alternatives to indwelling ureteral stents. <i>Progres En Urologie</i> , 2021, 31, 598-604.	0.3	2

#	ARTICLE	IF	CITATIONS
91	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. Asian Journal of Andrology, 2021, 23, 520.	0.8	2
92	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie. Cancers, 2021, 13, 6070.	1.7	2
93	Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer. Journal of Clinical Urology, 2020, 13, 425-436.	0.1	1
94	Small intestinal submucosa xenograft to manage lower urinary tract prostheses perforation: a new path?. International Urogynecology Journal, 2022, 33, 627-635.	0.7	1
95	The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 497.e1-497.e8.	0.8	1
96	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. Asian Journal of Andrology, 2021, 23, 370.	0.8	1
97	Long-term survival benefit from dual kidney transplantation using kidneys from donors with very extended criteria—a French cohort between 2002 and 2014. Nephrology Dialysis Transplantation, 2022, 37, 982-990.	0.4	1
98	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. International Journal of Surgical Pathology, 2023, 31, 157-166.	0.4	1
99	Prognosis factors in localised and metastatic renal cell carcinoma. Oncologie, 2009, 11, 260-266.	0.2	0
100	Quand attendre un dosage de la testostérone chez un patient ayant un cancer de prostate?. Progrès En Urologie - FMC, 2011, 21, F80-F85.	0.2	0
101	Comment suivre un schéma d'instillation du BCG en toute sécurité en 2013?. Progrès En Urologie - FMC, 2013, 23, F40-F46.	0.2	0
102	Effects of Adenosine Monophosphate Used in Combination with L-Arginine on Female Rabbit Corpus Cavernosum Tissue. Sexual Medicine, 2014, 2, 1-7.	0.9	0
103	Cáncer de riñón en el paciente dializado y en el paciente trasplantado. EMC - Urología, 2014, 46, 1-10.	0.0	0
104	Quelles ordonnances l'urologue doit-il rédiger pour initier et suivre une immunothérapie?. Progrès En Urologie - FMC, 2018, 28, F51-F54.	0.2	0
105	Quality of life outcomes after neobladder and ileal conduit following cystectomy for bladder cancer using a validated bladder-specific instrument: A prospective multi-institutional study.. Journal of Clinical Oncology, 2016, 34, 359-359.	0.8	0
106	Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy. Progres En Urologie, 2021, 32, 53-53.	0.3	0